1
|
Ghosh K, Bhardwaj B, Amin SA, Jha T, Gayen S. Identification of structural fingerprints for ABCG2 inhibition by using Monte Carlo optimization, Bayesian classification, and structural and physicochemical interpretation (SPCI) analysis. SAR AND QSAR IN ENVIRONMENTAL RESEARCH 2020; 31:439-455. [PMID: 32539470 DOI: 10.1080/1062936x.2020.1771769] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/13/2020] [Accepted: 05/17/2020] [Indexed: 06/11/2023]
Abstract
The human breast cancer resistance protein (BCRP), one of the members of the large ATP binding cassette (ABC) transporter superfamily, is crucial for resistance against chemotherapeutic agents. Currently, it has been emerged as one of the best biological targets for the designing of small molecule drugs capable of eliminating multidrug resistance in breast cancer. In order to gain insights into the relationship between the molecular structure of compounds and the ABCG2 inhibition, a multi-QSAR approach using different methods was performed on a dataset of 294 ABCG2 inhibitors with diverse scaffolds. The best models obtained by different chemometric methods have the following statistical characteristics: Monte Carlo Optimization-based QSAR (sensitivity = 0.905, specificity = 0.6255, accuracy = 0.756, and MCC = 0.545), Bayesian classification model (sensitivity = 0.735, specificity = 0.775, and concordance = 0.757); structural and physicochemical interpretation analysis-random forest method (balance accuracy = 0.750, sensitivity = 0.810, and specificity = 0.700). Additionally, structural fingerprints modulating the ABCG2 inhibitory properties were identified from the best models of each method and also validated with each other. The current modelling study is an attempt to get a deep insight into the different important structural fingerprints modulating ABCG2 inhibition.
Collapse
Affiliation(s)
- K Ghosh
- Laboratory of Drug Design and Discovery, Department of Pharmaceutical Sciences, Dr. H. S. Gour University , Sagar, India
| | - B Bhardwaj
- Laboratory of Drug Design and Discovery, Department of Pharmaceutical Sciences, Dr. H. S. Gour University , Sagar, India
| | - S A Amin
- Natural Science Laboratory, Division of Medicinal and Pharmaceutical Chemistry, Department of Pharmaceutical Technology, Jadavpur University , Kolkata, India
| | - T Jha
- Natural Science Laboratory, Division of Medicinal and Pharmaceutical Chemistry, Department of Pharmaceutical Technology, Jadavpur University , Kolkata, India
| | - S Gayen
- Laboratory of Drug Design and Discovery, Department of Pharmaceutical Sciences, Dr. H. S. Gour University , Sagar, India
| |
Collapse
|
3
|
Safar Z, Kis E, Erdo F, Zolnerciks JK, Krajcsi P. ABCG2/BCRP: variants, transporter interaction profile of substrates and inhibitors. Expert Opin Drug Metab Toxicol 2019; 15:313-328. [PMID: 30856014 DOI: 10.1080/17425255.2019.1591373] [Citation(s) in RCA: 33] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
INTRODUCTION ABCG2 has a broad substrate specificity and is one of the most important efflux proteins modulating pharmacokinetics of drugs, nutrients and toxicokinetics of toxicants. ABCG2 is an important player in transporter-mediated drug-drug interactions (tDDI). Areas covered: The aims of the review are i) to cover transporter interaction profile of substrates and inhibitors that can be utilized to test interaction of drug candidates with ABCG2, ii) to highlight main characteristics of in vitro testing and iii) to describe the structural basis of the broad substrate specificity of the protein. Preclinical data utilizing Abcg2/Bcrp1 knockouts and clinical studies showing effect of ABCG2 c.421C>A polymorphism on pharmacokinetics of drugs have provided evidence for a broad array of drug substrates and support drug - ABCG2 interaction testing. A consensus on using rosuvastatin and sulfasalazine as intestinal substrates for clinical studies is in the formation. Other substrates relevant to the therapeutic area can be considered. Monolayer efflux assays and vesicular transport assays have been extensively utilized in vitro. Expert opinion: Clinical substrates display complex pharmacokinetics due to broad interaction profiles with multiple transporters and metabolic enzymes. Substrate-dependent inhibition has been observed for several inhibitors. Harmonization of in vitro and in vivo testing makes sense. However, rosuvastatin and sulfasalazine are not efficiently transported in either MDCKII or LLC-PK1-based monolayers. Caco-2 monolayer assays and vesicular transport assays are potential alternatives.
Collapse
Affiliation(s)
| | - Emese Kis
- a SOLVO Biotechnology , Szeged , Hungary
| | - Franciska Erdo
- b Faculty of Information Technology and Bionics , Pázmány Péter Catholic University , Budapest , Hungary
| | | | - Peter Krajcsi
- a SOLVO Biotechnology , Szeged , Hungary.,d Department of Morphology and Physiology. Faculty of Health Sciences , Semmelweis University , Budapest , Hungary
| |
Collapse
|
5
|
Spindler A, Stefan K, Wiese M. Synthesis and Investigation of Tetrahydro-β-carboline Derivatives as Inhibitors of the Breast Cancer Resistance Protein (ABCG2). J Med Chem 2016; 59:6121-35. [PMID: 27280693 DOI: 10.1021/acs.jmedchem.6b00035] [Citation(s) in RCA: 51] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
The breast cancer resistance protein (ABCG2) transports chemotherapeutic drugs out of cells, which makes it a major player in mediating multidrug resistance (MDR) of cancer cells. To overcome this mechanism, inhibitors of ABCG2 can be used. Only a few potent and selective ABCG2 inhibitors have been discovered, i.e., fumitremorgin C (FTC), Ko143, and the alkaloid harmine, which contain a tetrahydro-β-carboline or β-carboline backbone, respectively. However, toxicity and or instability prevent their use in vivo. Therefore, there is a need for further potent inhibitors. We synthesized and pharmacologically investigated 37 tetrahydro-β-carboline derivatives. The inhibitory activity of two compounds (51, 52) is comparable to that of Ko143, and they are selective for ABCG2 over ABCB1. Furthermore, they are able to reverse the ABCG2-mediated resistance toward SN-38 and inhibit the ATPase activity. The cytotoxicity data show that their inhibitory effect is substantially higher than their toxicity.
Collapse
Affiliation(s)
- Anna Spindler
- Pharmaceutical Institute, University of Bonn , An der Immenburg 4, 53121 Bonn, Germany
| | - Katja Stefan
- Pharmaceutical Institute, University of Bonn , An der Immenburg 4, 53121 Bonn, Germany
| | - Michael Wiese
- Pharmaceutical Institute, University of Bonn , An der Immenburg 4, 53121 Bonn, Germany
| |
Collapse
|
6
|
Weidner LD, Zoghbi SS, Lu S, Shukla S, Ambudkar SV, Pike VW, Mulder J, Gottesman MM, Innis RB, Hall MD. The Inhibitor Ko143 Is Not Specific for ABCG2. J Pharmacol Exp Ther 2015; 354:384-93. [PMID: 26148857 DOI: 10.1124/jpet.115.225482] [Citation(s) in RCA: 91] [Impact Index Per Article: 10.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2015] [Accepted: 06/26/2015] [Indexed: 11/22/2022] Open
Abstract
Imaging ATP-binding cassette (ABC) transporter activity in vivo with positron emission tomography requires both a substrate and a transporter inhibitor. However, for ABCG2, there is no inhibitor proven to be specific to that transporter alone at the blood-brain barrier. Ko143 [[(3S,6S,12aS)-1,2,3,4,6,7,12,12a-octahydro-9-methoxy-6-(2-methylpropyl)-1,4-dioxopyrazino[1',2':1,6]pyrido[3,4- b]indole-3-propanoic acid 1,1-dimethylethyl ester], a nontoxic analog of fungal toxin fumitremorgin C, is a potent inhibitor of ABCG2, although its specificity in mouse and human systems is unclear. This study examined the selectivity of Ko143 using human embryonic kidney cell lines transfected with ABCG2, ABCB1, or ABCC1 in several in vitro assays. The stability of Ko143 in rat plasma was measured using high performance liquid chromatography. Our results show that, in addition to being a potent inhibitor of ABCG2, at higher concentrations (≥1 μM) Ko143 also has an effect on the transport activity of both ABCB1 and ABCC1. Furthermore, Ko143 was found to be unstable in rat plasma. These findings indicate that Ko143 lacks specificity for ABCG2 and this should be taken into consideration when using Ko143 for both in vitro and in vivo experiments.
Collapse
Affiliation(s)
- Lora D Weidner
- Molecular Imaging Branch, National Institute of Mental Health, Bethesda, Maryland (L.D.W., S.S.Z., S.L., V.W.P., R.B.I.); Karolinska Institutet, Department of Neuroscience, Stockholm, Sweden (L.D.W., J.M.); and Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland (S.S., S.V.A., M.M.G., M.D.H.)
| | - Sami S Zoghbi
- Molecular Imaging Branch, National Institute of Mental Health, Bethesda, Maryland (L.D.W., S.S.Z., S.L., V.W.P., R.B.I.); Karolinska Institutet, Department of Neuroscience, Stockholm, Sweden (L.D.W., J.M.); and Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland (S.S., S.V.A., M.M.G., M.D.H.)
| | - Shuiyu Lu
- Molecular Imaging Branch, National Institute of Mental Health, Bethesda, Maryland (L.D.W., S.S.Z., S.L., V.W.P., R.B.I.); Karolinska Institutet, Department of Neuroscience, Stockholm, Sweden (L.D.W., J.M.); and Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland (S.S., S.V.A., M.M.G., M.D.H.)
| | - Suneet Shukla
- Molecular Imaging Branch, National Institute of Mental Health, Bethesda, Maryland (L.D.W., S.S.Z., S.L., V.W.P., R.B.I.); Karolinska Institutet, Department of Neuroscience, Stockholm, Sweden (L.D.W., J.M.); and Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland (S.S., S.V.A., M.M.G., M.D.H.)
| | - Suresh V Ambudkar
- Molecular Imaging Branch, National Institute of Mental Health, Bethesda, Maryland (L.D.W., S.S.Z., S.L., V.W.P., R.B.I.); Karolinska Institutet, Department of Neuroscience, Stockholm, Sweden (L.D.W., J.M.); and Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland (S.S., S.V.A., M.M.G., M.D.H.)
| | - Victor W Pike
- Molecular Imaging Branch, National Institute of Mental Health, Bethesda, Maryland (L.D.W., S.S.Z., S.L., V.W.P., R.B.I.); Karolinska Institutet, Department of Neuroscience, Stockholm, Sweden (L.D.W., J.M.); and Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland (S.S., S.V.A., M.M.G., M.D.H.)
| | - Jan Mulder
- Molecular Imaging Branch, National Institute of Mental Health, Bethesda, Maryland (L.D.W., S.S.Z., S.L., V.W.P., R.B.I.); Karolinska Institutet, Department of Neuroscience, Stockholm, Sweden (L.D.W., J.M.); and Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland (S.S., S.V.A., M.M.G., M.D.H.)
| | - Michael M Gottesman
- Molecular Imaging Branch, National Institute of Mental Health, Bethesda, Maryland (L.D.W., S.S.Z., S.L., V.W.P., R.B.I.); Karolinska Institutet, Department of Neuroscience, Stockholm, Sweden (L.D.W., J.M.); and Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland (S.S., S.V.A., M.M.G., M.D.H.)
| | - Robert B Innis
- Molecular Imaging Branch, National Institute of Mental Health, Bethesda, Maryland (L.D.W., S.S.Z., S.L., V.W.P., R.B.I.); Karolinska Institutet, Department of Neuroscience, Stockholm, Sweden (L.D.W., J.M.); and Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland (S.S., S.V.A., M.M.G., M.D.H.)
| | - Matthew D Hall
- Molecular Imaging Branch, National Institute of Mental Health, Bethesda, Maryland (L.D.W., S.S.Z., S.L., V.W.P., R.B.I.); Karolinska Institutet, Department of Neuroscience, Stockholm, Sweden (L.D.W., J.M.); and Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland (S.S., S.V.A., M.M.G., M.D.H.)
| |
Collapse
|